skip to main |
skip to sidebar
Free Stuff
SUBSCRIBE
Contributors
Labels
- "at risk" (1)
- "spec" pharma (2)
- 12-step program (1)
- AACR (1)
- Abbott (4)
- Abigail Alliance (1)
- Abingworth (1)
- ABR (1)
- Acambis (1)
- ACC (1)
- Acceleron (2)
- Acclarent (1)
- ACE (1)
- Acomplia (2)
- acronyms (1)
- Actelion (2)
- Actimis (1)
- Active Surveillance (2)
- activist shareholders (4)
- Actos (1)
- ADA (1)
- Addex (4)
- ADHD (2)
- Adimab (1)
- adjuvants (1)
- Adnexus (3)
- Advanced Technology Ventures (1)
- advisory committees (19)
- advocacy (1)
- Agents for Change (1)
- AHRQ (1)
- Aisling (1)
- Akzo Nobel (1)
- Alantos (1)
- Albireo (1)
- Alcon (2)
- Alex Azar (1)
- Alfacell (1)
- Alkermes (1)
- Allergan (1)
- alli (2)
- alliances (39)
- alliteration (1)
- Allthingsd (1)
- ally-to-buy (1)
- Alnylam (7)
- Alsius (1)
- Alzheimer's disease (4)
- Ambrx (1)
- Amgen (30)
- Amicus (1)
- Amira (1)
- Amylin (2)
- Anadys (1)
- Andrew von Eschenbach (11)
- Angiotech (2)
- Animal Health (2)
- annus horribilis (1)
- anti-aging (1)
- antibodies (1)
- antisense (1)
- Antisense Therapeutics (1)
- Antisoma (2)
- Applied Biosystems (2)
- ARBs (1)
- Ares (1)
- Arlo Guthrie (1)
- Arrow International (1)
- Arterial Remodeling Technologies (1)
- Aryx (2)
- Ascension Health Ventures (1)
- ASCO (5)
- ASH (1)
- Asia (1)
- Aspreva (1)
- Astellas (3)
- Astex (1)
- Asthmatx (1)
- AstraZeneca (26)
- athenahealth (2)
- Atlas Venture (5)
- attempts at photoshop (1)
- audio conference (1)
- Austin Powers (1)
- autism (1)
- Avandia (23)
- Avant (1)
- Avastin (7)
- bad news (2)
- Badly Burned (1)
- Bain (1)
- bandwagon (1)
- Barack Obama (3)
- Barr (2)
- Barrier (1)
- baseball (3)
- Batman (1)
- battle of the budget numbers (2)
- Baucus (1)
- Bausch and Lomb (1)
- Baxter (3)
- Bayer (7)
- Bayer-Schering Pharma (4)
- BCG survey (1)
- Beckman-Coulter (1)
- behind-the-counter (1)
- Benelux (1)
- Bentley (1)
- Bial (1)
- Big Management (1)
- Big Pharma (14)
- Big Pharma outlicensing (1)
- Bigfoot (1)
- Bill Freytag (1)
- BIO (5)
- Biogen Idec (13)
- BiogenIdec (1)
- BioInvent (1)
- BioLineRx (1)
- Biolipox (1)
- biologics (4)
- BioLucent (1)
- Biomet (2)
- BioMS (1)
- bioresorbable stents (2)
- bioshield (1)
- biosimilars (6)
- Biosite (2)
- Biovitrum (1)
- BiPar Sciences (1)
- Birdhouse in Your Soul (1)
- bit on the side (1)
- blockbuster (1)
- blogging (3)
- BMS (10)
- Bo Diddley (1)
- Bob Dylan (1)
- Boehringer Ingelheim (2)
- bone mineralization (1)
- Bono (1)
- Boston Celtics (1)
- Boston Consulting Group; Hot Therapeutic Areas (1)
- boston parochialism (1)
- Boston Scientific (8)
- Botox (1)
- brand names (4)
- brave new world (1)
- Brian Unger (1)
- Bristol-Myers Squibb (10)
- Broncus (1)
- budget request (3)
- Byetta (2)
- C-SPAN (1)
- cabbage wagon (1)
- Caddyshack (1)
- Calpers (1)
- Campbell Alliance (2)
- Canaan (1)
- cancer diagnostics (1)
- cancer vaccines (5)
- Canopy (1)
- Cardinal Partners (1)
- CardioNet (3)
- Cardiovascular Systems (1)
- Carl Icahn (8)
- Carlton Fisk (1)
- carried interest (1)
- Carson (1)
- Catch-22 (1)
- CBO (2)
- CCMPP (1)
- CDER (3)
- CDER Director (2)
- CEDDs (2)
- Celebrex (1)
- Celgene (7)
- Cell Genesys (2)
- Cell Therapeutics (1)
- cell therapy (2)
- Celtic Pharma (4)
- Cenes (1)
- Cephalon (3)
- CFOs (1)
- Chantix (1)
- China (6)
- Chorus (1)
- Cierra (1)
- Cimzia (2)
- Citi (1)
- Citigroup (1)
- Clal Biotechnologies (1)
- Clarus (4)
- Clement Moore (1)
- cliches (2)
- Climate of Calamity (1)
- clinical development (15)
- CMEA (1)
- CMS (14)
- CNS (1)
- co-promotes (5)
- CoAptus Medical (1)
- Coffee (1)
- Cogenesys (1)
- Coke (1)
- Cole Werble (1)
- Coley (2)
- combination drugs (1)
- CoMentis (1)
- commissioner succession plan (1)
- comparative effectiveness (4)
- ConcepTx (1)
- conference (5)
- conflict of interest (1)
- Confluent Surgical (1)
- Congress (9)
- consumer genomics (3)
- consumer marketing (2)
- Cordaptive (1)
- Corin (1)
- corporate culture (1)
- corporate governance (1)
- corporate venture capital (2)
- corporate venturing (1)
- cost issues (2)
- cost-cutting (1)
- Covance (1)
- Covidien (1)
- CovX (1)
- Craig Maxwell (1)
- Credibility (1)
- Crucell (1)
- CryoCor (1)
- Cubist (2)
- Curagen (1)
- Curis (1)
- Cutlass (1)
- CV Therapeutics (1)
- CVS Caremark (1)
- Cyberheart (1)
- Cyberonics (1)
- Cypress (1)
- Cytogen (2)
- Cytyc (3)
- Daiichi Sankyo (6)
- Dalton (1)
- Dane Wittrup (1)
- David Brailer (2)
- David Cassak (1)
- David Flockhart (1)
- David Kessler (2)
- David Mott (1)
- Deadspin (1)
- deals are like snowflakes (1)
- deals of the week (1)
- debt financing (3)
- deCODE (2)
- deja vu (1)
- Delays (1)
- Delphi (2)
- Democrats (1)
- demon seed (1)
- Dendreon (2)
- denosumab (1)
- DePuy Spine (3)
- Deuchar's IPA (2)
- Deutsche Bank (1)
- device envy (1)
- Diabetes (14)
- diagnostics (2)
- Diamics (1)
- Dicerna (3)
- Dick Clark (2)
- Dingell (1)
- direct hires (2)
- direct-to-pharmacy (1)
- dirty word (1)
- disaggregation (2)
- Divorce (1)
- docs decide (1)
- dodgy communications (1)
- Dollens (2)
- Dolsten (1)
- Domain Associates (3)
- double-dip (2)
- Dow Jones (2)
- DPP-IV (2)
- Dr Reddy's (1)
- dragon (1)
- drug approvals (13)
- drug delivery (4)
- drug discovery (2)
- drug eluting stents (3)
- drug launch (1)
- Drug Pricing (8)
- drug safety (47)
- drug samples (1)
- DTC Advertising (14)
- dumb luck (1)
- Dyax (2)
- Dynepo (1)
- Dynogen (2)
- e-health (1)
- E-prescribing (1)
- earnings (1)
- Easton (1)
- Eckard Weber (1)
- Edmund de Rothschild (1)
- Edwards Life Sciences (1)
- Effient (1)
- egg-on-face (1)
- Eisai (3)
- Elan (3)
- Elevation Partners (1)
- Eli Lilly (34)
- Elixir Pharmaceuticals (1)
- Elron (1)
- Emageon (1)
- Emergent Medical Ventures (1)
- Emisphere (2)
- Emphasys (2)
- emphysema (1)
- Encysive (1)
- end of an era (1)
- Endo (4)
- Endo Pharmaceuticals (2)
- Endosense (1)
- endovascular (1)
- ENHANCE (1)
- Entereg (1)
- EnteroMedics (1)
- Enterprise Partners (1)
- Enzon (1)
- epo (15)
- erectile dysfunction (1)
- Esperion (1)
- Essex Woodlands (1)
- Estee Lauder (1)
- Ethicon (1)
- EuclidSR (1)
- Euro-Biotech Forum (4)
- Euronext (1)
- European biotech (4)
- European infrastructure (2)
- EUSA (3)
- EV3 (2)
- Evalve (1)
- Excalibur (1)
- executioner (1)
- executive accountability (1)
- Exits (1)
- expanded access (1)
- extended boxing metaphors (1)
- extended Christmas analogies (1)
- Exubera (12)
- eyeonics (1)
- FDA (117)
- FDA postmarket controls (2)
- FDA/CMS Summit (3)
- FDAAA (6)
- Fentora (2)
- financing (19)
- finding predictability (1)
- FIPCO (1)
- First Pitch (1)
- Fischell Family (1)
- FivePrime (1)
- FOBs (2)
- Fogarty (1)
- follow-on biologics (5)
- For Sale By Owner (1)
- Forest Labs (3)
- Forsight (1)
- Fox Hollow (2)
- Frank Baldino (1)
- Frank Torti (1)
- Frazier Healthcare (3)
- Fresenius (2)
- Friday night (1)
- frothy (1)
- Frova (2)
- fun with the classics (2)
- Galapagos (2)
- Galderma (1)
- Galenica (1)
- Galvus (2)
- gastro-intestinal research (2)
- Gen-Probe (1)
- Gene Logic (1)
- gene therapy (3)
- Genentech (13)
- General Electric (4)
- generics (11)
- genmab (2)
- Genomic Health (1)
- genomics (1)
- Genzyme (9)
- George Bush (1)
- George Thorogood and the Destroyers (1)
- Germany (1)
- getting in with locals (1)
- Ghost of Christmas Yet to Come (1)
- Given (1)
- Glaucoma (1)
- GlaxoSmithKline (10)
- Gleevec (1)
- Globus (2)
- GLP-1s (3)
- glucose monitoring (1)
- GlycoFi (2)
- glycosaminoglycans (1)
- going specialist (1)
- Google (2)
- GPC (3)
- Grassley (3)
- Greed is Good (1)
- GSK (45)
- GTx (1)
- Guidant (1)
- Hadasit (1)
- haircuts (3)
- Half jokes (1)
- Hamlet (1)
- hands-off (1)
- Happy Holidays (1)
- Haptogen (1)
- Harrigan (1)
- Harry Potter (1)
- HBM BioVentures (1)
- HBO (1)
- HCV (1)
- Headhunting (2)
- Health care IT (1)
- Health Care Reform (1)
- hedge funds (2)
- Henry Waxman (1)
- heparin (7)
- hepatitis C (2)
- hGH (2)
- Hillary Clinton (5)
- hiring frenzy (1)
- HNH (1)
- Hologic (3)
- Homer Simpson (1)
- Hopium (1)
- Hospital (1)
- hostile offers (2)
- hostile takeovers (4)
- Hunter-Fleming (1)
- hurricanes (1)
- hype (2)
- hypertension (2)
- IBS (2)
- Idenix (3)
- Idera Pharmaceuticals (1)
- Idev (1)
- IDM Pharma (1)
- IHC (1)
- Ilypsa (2)
- ImClone (1)
- IMS Health (3)
- In vitro diagnostics (3)
- IN VIVO (1)
- In3 (4)
- India (4)
- Indians (1)
- influenza (1)
- Innogenetics (2)
- insomnia (6)
- instrumentation (1)
- insulin (6)
- Inteleos (1)
- Intercell (4)
- InterWest (1)
- Inverness (4)
- Investigation (1)
- investment banks (1)
- Invitrogen (1)
- Invus (1)
- Iomai (1)
- IP (2)
- Iphone (1)
- IPO (6)
- IPO pricing (8)
- Ipsen (2)
- Irotek (1)
- ISH (1)
- Isis (3)
- Isis Pharmaceuticals (1)
- Israel (1)
- IST (1)
- IT (1)
- it's how they roll (1)
- JAMA (2)
- Janet Woodcock (8)
- Janssen (1)
- Januvia (4)
- Japan (3)
- Japanese encephalitis (1)
- Jazz (1)
- Jeff Kindler (1)
- Jerini (1)
- Jerry Springer (1)
- Jim Cornelius (1)
- John Crowley (1)
- John Henry (1)
- John Jenkins (2)
- John Lithgow sitcoms (1)
- John McCain (2)
- Johns Hopkins (1)
- Johnson and Johnson (23)
- Jonathan Bush (1)
- JP Morgan (6)
- JPM (1)
- KAI (2)
- Kalypsys (1)
- Kamada (1)
- Kearny Street (1)
- Kendall (1)
- Kennebunkport (1)
- Ketek (2)
- Kim (1)
- King Pharmaceuticals (1)
- KKR (3)
- Kleiner Perkins (3)
- Kosan (2)
- Kyowa (1)
- Kyowa Hakko (1)
- Kyphon (2)
- la-la land (1)
- LABAs (1)
- LaMattina (2)
- Langer (1)
- late-stage deal (1)
- lawsuits (3)
- layoffs (4)
- learning (1)
- legislation (9)
- Lethal Weapon (1)
- Lev (1)
- Lifecore (1)
- Lipitor (4)
- Liposonix (1)
- little brains (1)
- lobbying (1)
- long-shot (1)
- Longitude Capital (1)
- love birds (1)
- Lucentis (4)
- Lundbeck (3)
- Lunesta (1)
- Lupus (1)
- Lux BioSciences (1)
- MacroGenics (2)
- mail service pharmacy (1)
- Mailbag (1)
- managed care (1)
- management succession (7)
- Mannkind (1)
- march madness (1)
- Mark McClellan (3)
- marketing (3)
- marketing disaster (1)
- Marriage (1)
- Martin Mackay (1)
- Matrimony (1)
- Maverick (1)
- Maxygen (1)
- MDRNA (2)
- Medco Health Soultions (1)
- Medicaid Fraud (1)
- medical device financing (1)
- Medical Device Today (1)
- Medical Device VCs (1)
- medical devices (5)
- Medicare (9)
- Medicare Part D (2)
- medication errors (1)
- Medicis (1)
- MediGene (1)
- Medimmune (6)
- Medivir (1)
- Medrad (1)
- Medtech Insight (1)
- Medtronic (8)
- Medtronic Sofamar Danek (1)
- Merck (35)
- Merck-Serono (1)
- merger integration (1)
- mergers and acquisitions (68)
- Meritech (1)
- Merlin (1)
- Mesa Verde (1)
- metabolic (1)
- metamorphosis (1)
- MetroNorth (1)
- MGH (1)
- MGI (3)
- Michael Clayman (1)
- michael landon (1)
- Michael McCaughan (1)
- Michael Moore (1)
- Michael Yeomans (1)
- microRNA (1)
- Microsoft (1)
- microtargeting (1)
- migraine (1)
- Millenium (1)
- Millennium (4)
- Mircera (1)
- Misleading PR (1)
- missing user fee deadlines (1)
- Mitchell (2)
- mixed bag (1)
- mmm beer (1)
- Mochida Pharmaceuticals (1)
- molecular diagnostics (2)
- MolMed (1)
- Momenta (2)
- Moody's (1)
- Morgan Stanley (1)
- Morgenthaler (2)
- Morphosys (2)
- Morphotek (1)
- Mother's Day (1)
- MPM (5)
- Mr. Bill (1)
- MRI (2)
- multiple sclerosis (2)
- muraglitazar (1)
- MVM (1)
- Myogen (1)
- Myriad Genetics (3)
- nail in the coffin (1)
- nanotechnology (1)
- NASA (1)
- Nastech (2)
- National Medal of Science (1)
- Nature (1)
- Natus Medical (1)
- Neil Diamond (1)
- NEJM (3)
- Nektar (1)
- Nestle (1)
- Neurimmune (1)
- Neurochem (1)
- neurology (1)
- Neuromed (1)
- neuromodulation (1)
- neurostimulation (1)
- new drug approvals (1)
- New Enterprise Associates (2)
- new funds (4)
- New Leaf Ventures (1)
- New Mountain (1)
- New Year's resolutions (1)
- New York Times (2)
- Newron (1)
- Nexium (1)
- Next Big Thing (1)
- NICE (3)
- NicOx (2)
- NIH (1)
- nit-picking (1)
- NMT Medical (1)
- Nobel Prize (1)
- Nomura (1)
- non-confrontational academic (1)
- non-profits (1)
- Northstar Neuroscience (1)
- Northwest Biotherapeutics (2)
- NovaMed (1)
- Novartis (35)
- Novexel (1)
- Novo AS (1)
- Novo Nordisk (7)
- Nplate (1)
- nursing homes (1)
- NuVasive (1)
- NVCA (3)
- Nycomed (1)
- obesity (2)
- Octagen (1)
- ODAC (3)
- off-label promotion (3)
- OncoGenex (1)
- oncology (17)
- ooh la la (1)
- Open Biosystems (1)
- ophthalmology (3)
- Ophthotech (1)
- Oracle Healthcare (2)
- Orexo (1)
- Organon (2)
- Orion Health Care (2)
- Orthopedics (2)
- Osiris (1)
- osteoporosis (2)
- OTC drugs (2)
- Otsuka (1)
- out-licensing (2)
- Out-Partnering (2)
- outsourcing (3)
- oversleeping (1)
- Oxford Bioscience Partners (4)
- Oxycontin (2)
- PAH (1)
- pain (5)
- painful memories (1)
- Paion (1)
- pajama party (1)
- Palo Alto Investors (1)
- Pappas Ventures (1)
- parallel reviews (1)
- Paris (1)
- Parkinson's disease (2)
- parsing (1)
- Part D (2)
- Paul Capital (2)
- Paul Stoffels (1)
- PBMs (1)
- PDL (1)
- PDUFA (5)
- Pelikan (1)
- Penumbra (1)
- Perlegen (1)
- Perlmutter (1)
- personalized medicine (7)
- Pfizer (38)
- pharma marketing (1)
- Pharmacopeia (1)
- pharmacy benefits (2)
- PharmAsiaNews (1)
- Pharmion (3)
- Philadelphia Eagles (1)
- Philadelphia Phillies (2)
- Philips (1)
- PhRMA (5)
- PhRMA Code of Ethics (1)
- physician gifts (1)
- pilot scheme (1)
- Pinyons (1)
- PIramed (2)
- Plethora Solutions (1)
- Plexxikon (1)
- POC model (1)
- point-of-care (2)
- Polaris (1)
- Polaris Venture Partners (4)
- Police (1)
- political influence (1)
- politics (7)
- poll results (2)
- portfolio management (1)
- Portola (1)
- Possis Medical (1)
- post-marketing studies (1)
- Pozen (1)
- PPAR agonists (2)
- PR (2)
- prasugrel (7)
- Precision Therapeutics (2)
- pregnancy (1)
- Presidential Election (5)
- Presidio Pharmaceuticals (1)
- Press Release of the Week (3)
- Primary Care (4)
- prions (1)
- private equity (6)
- problematic labels (1)
- Procter and Gamble (2)
- Proctor and Gamble (1)
- Product Liability (1)
- Promacta (1)
- Protez Pharmaceuticals (1)
- PSA (8)
- PSO (3)
- psychedelic government emblems (2)
- psychiatric adverse events (1)
- PTC (1)
- Public Citizen (1)
- public health (1)
- publication delays (1)
- Purdue Pharma (2)
- purple slippers (1)
- Pyrrhic victory (1)
- QLT (1)
- R.E.M. (2)
- Radius (1)
- Ranbaxy (5)
- RaQualia (2)
- rare diseases (3)
- Raven (2)
- Reagan-Udall Foundation (2)
- Real Ale (2)
- real money (1)
- records (1)
- Red Sox In Seven (1)
- Redux (1)
- Reed-Elsevier (2)
- regeneron (1)
- regulatory risk (1)
- Regulus (1)
- Regulus Therapeutics (1)
- reimbursement (12)
- Reliance (1)
- Reliant Technologies (2)
- Remon Medical Technologies (1)
- REMS (4)
- reprofiling (1)
- Republicans (1)
- reruns (3)
- research and development expenditures (1)
- research and development productivity (2)
- research and development strategies (17)
- Research employment; restructuring (1)
- Restore Medical (1)
- resveratrol (2)
- REVA (1)
- Rezulin (1)
- Rheoscience (1)
- Riddler (1)
- rimonabant (5)
- risk communication (1)
- risk management (3)
- RiskMAP (4)
- risky business (1)
- Rivervest (1)
- RNAi (9)
- Roadside Bombs (1)
- Robert Langer (1)
- Roche (18)
- Roger Longman (5)
- Ron Burgundy (1)
- royalties (1)
- rubbing shoulders (1)
- Ruffolo (1)
- Safety First (2)
- Sai (1)
- Saints Capital (1)
- sales force cuts (1)
- sales forces (1)
- San Diego (1)
- Sanderling (1)
- Sandoz (1)
- Sanofi Aventis (5)
- Sanofi-aventis (14)
- Santaris (2)
- Sapient (1)
- SARMs (1)
- Satan (1)
- satraplatin (2)
- Scale Venture Partners (2)
- schadenfreude (1)
- Schering Plough (5)
- Schering-Plough (12)
- schizophrenia (1)
- Science Board (1)
- Science Matters (6)
- Scil Technology (2)
- Scott Gottlieb (1)
- Sentinel (1)